Dr. Povsic is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
6301 Herndon Rd
Durham, NC 27713Phone+1 919-681-5816
Education & Training
- Duke University HospitalFellowship, Interventional Cardiology, 2003 - 2004
- Duke University HospitalFellowship, Cardiovascular Disease, 1998 - 2001
- Duke University HospitalResidency, Internal Medicine, 1995 - 1998
- Harvard Medical SchoolClass of 1995
Certifications & Licensure
- NC State Medical License 1997 - 2025
- VA State Medical License 1999 - 2008
- American Board of Internal Medicine Cardiovascular Disease
- American Board of Internal Medicine Interventional Cardiology
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2013
Clinical Trials
- Safety and Feasibility Trial of Adipose-Derived Regenerative Cells in the Treatment of Chronic Myocardial Ischemia Start of enrollment: 2012 Jun 01
Publications & Presentations
PubMed
- 10 citationsEffect of Reconstituted Human Apolipoprotein A-I on Recurrent Ischemic Events in Survivors of Acute MI.Thomas J Povsic, Serge Korjian, M Cecilia Bahit, Gerald Chi, Danielle Duffy
Journal of the American College of Cardiology. 2024-06-04 - 27 citationsApolipoprotein A1 Infusions and Cardiovascular Outcomes after Acute Myocardial Infarction.C Michael Gibson, Danielle Duffy, Serge Korjian, M Cecilia Bahit, Gerald Chi
The New England Journal of Medicine. 2024-05-02 - 2 citationsAngiogenic Gene Therapy for Refractory Angina: Results of the EXACT Phase 2 Trial.Kenta Nakamura, Timothy D Henry, Jay H Traverse, David A Latter, Nahush A Mokadam
Circulation. Cardiovascular Interventions. 2024-05-01
Press Mentions
- BioCardia Announces First Patient Treated in CardiAMP Cell Therapy Trial for Chronic Myocardial IschemiaOctober 21st, 2021
- XyloCor Therapeutics Commences Phase 2 Component of Phase 1/2 EXACT Clinical Study of XC001 Gene Therapy for Refractory AnginaJuly 27th, 2021
- Access Denied: Stem Cell Therapy Shows Some Promise in Refractory Angina, but Patients Can’t Get ItMay 19th, 2017
- Join now to see all
Grant Support
- Assessing Circulating Progenitor Cells In Heart DiseaseNational Heart, Lung, And Blood Institute2006–2007
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: